Medigene expands end-to-end technology platform through worldwide, exclusive license of a CD40L-CD28 Costimulatory Switch Receptor further enhancing potential to treat solid tumors

Medigene AG reports it has partnered with Helmholtz Munich to acquire the exclusive, worldwide rights to the CD40L-CD28 costimulatory switch receptor adding to the portfolio of technologies within Medigene’s end-to-end platform.